🇺🇸 FDA
Patent

US 11661455

Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety

granted A61KA61K2039/505A61P

Quick answer

US patent 11661455 (Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety) held by Orionis Biosciences, Inc expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Orionis Biosciences, Inc
Grant date
Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61P, A61P35/00